CLINICAL TRIAL SERVICES AGREEMENT This Agreement is made and entered into this 16th day of March 2007 by and between: HARVARD CLINICAL RESEARCH INSTITUTE, INC. ("HCRI") 930 Commonwealth Avenue Boston, Massachusetts 02215Clinical Trial Services Agreement • April 5th, 2007 • Vicor Technologies, Inc. • Surgical & medical instruments & apparatus • Massachusetts
CLINICAL TRIAL SERVICES AGREEMENTClinical Trial Services Agreement • October 2nd, 2012 • Advaxis, Inc. • Pharmaceutical preparations • Pennsylvania
This Clinical Trial Services Agreement (“Agreement”) is between Advaxis, Inc. (“Sponsor”) , a for-profit corporation organized under the laws of Delaware, USA and holder of IND Number 13712, and the Gynecologic Oncology Group (“GOG”) , a not-for-profit corporation organized under the laws of the District of Columbia, to conduct the Clinical Trial according to the Protocol attached as Exhibit A and incorporated by reference in this Agreement. The Principal Investigator for the GOG shall be Philip J. DiSaia, M.D. The Clinical Trial will be directed by Warner K. Huh, M.D. (“Study Chair”), according to the Protocol.
CLINICAL TRIAL SERVICES AGREEMENT*Clinical Trial Services Agreement • October 24th, 2011 • Radius Health, Inc. • Blank checks • New York
This Clinical Trial Services Agreement (this “Agreement”) is entered into as of March 29, 2011 (“Effective Date”) by and between RADIUS HEALTH, INC., a Delaware corporation (“Radius”) and NORDIC BIOSCIENCE CLINICAL DEVELOPMENT VII A/S, a Danish corporation (“NB”) that is a wholly-owned subsidiary of Nordic Bioscience Clinical Development A/S and sets forth the terms and conditions that will apply to the provision by NB to Radius of certain services.
Gilead Sciences, Inc. Clinical Trial Services Agreement GILEAD SCIENCES, INC. SMLOUVA O POSKYTOVÁNÍ SLUŽEB KLINICKÉHO HODNOCENÍClinical Trial Services Agreement • January 24th, 2021
This Clinical Trial Services Agreement (“Agreement”) is made effective as of 29th November, 2016 (“Effective Date”) by and between Gilead Sciences, Inc., a Delaware corporation having a principal place of business at 333 Lakeside Drive, Foster City, California 94404 (together with its affiliates and subsidiaries, “Gilead”) and Revmatologický ústav having an address at Na Slupi 4, 128 50, Praha 2, Czech Republic, company ID number: 00023728, DIČ: CZ00023728, represented by prof. MUDr. Karel Pavelka, DrSc., Director (“Service Provider”). Gilead and Service Provider are sometimes referred to herein individually as a “Party” and collectively as the “Parties.” Gilead has contracted with Pharmaceutical Research Associates CZ, s.r.o., located at Jankovcova 1569/2c, Praha 7, 170 00, Czech Republic, company ID number: 27636852, TAX ID number: CZ27636852, the limited liability company duly registered in the Commercial Register of the Czech Republic maintained by the Municipal Court in Prag
CLINICAL TRIAL SERVICES AGREEMENT AMENDMENT NO. 5 TO WORK STATEMENT NB-1Clinical Trial Services Agreement • May 20th, 2014 • Radius Health, Inc. • Blank checks
Pursuant to Section 2.3, 2.11 and 11.7 of the Agreement, the parties wish to enter into this Amendment No. 5 to Work Statement NB-1 (“Amendment No. 5”) effective as of May 19, 2014 (“Amendment Date”). Capitalized terms used in this Amendment No. 5 and not defined herein are used with the meanings ascribed to them in the Agreement and Work Statement NB-1.
CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THE EXHIBIT BECAUSE IT IS BOTH NOT MATERIAL AND IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. SUCH EXCLUDED INFORMATION HAS BEEN MARKED WITH “[***].” CHINA CLINICAL TRIAL...Clinical Trial Services Agreement • May 14th, 2024 • BioAtla, Inc. • Biological products, (no disgnostic substances)
This China Clinical Trial Services Agreement (“Agreement”), made as of this 8th day of April 2022 (the “Effective Date”), is by and between BioAtla, Inc. (“BioAtla”), a Delaware corporation having a place of business at 11085 Torreyana Road, San Diego, CA 92121 and Himalaya Therapeutics Limited Company, a company organized under the laws of Shanghai, having a registered office 3rd Floor, Building 2, No. 200 Zhangheng Road, China (Shanghai) Pilot Free Trade Zone (“Sponsor”). BioAtla and Sponsor are each referred to herein individually as a “Party” and collectively “Parties”.
CLINICAL TRIAL SERVICES AGREEMENT AMENDMENT NO. 4 TO WORK STATEMENT NB-1Clinical Trial Services Agreement • April 1st, 2014 • Radius Health, Inc. • Blank checks
Pursuant to Section 2.3, 2.11 and 11.7 of the Agreement, the parties wish to enter into this Amendment No. 4 to Work Statement NB-1 (“Amendment No. 4”) effective as of March 28, 2014 (“Amendment Date”). Capitalized terms used in this Amendment No. 4 and not defined herein are used with the meanings ascribed to them in the Agreement and Work Statement NB-1.
CLINICAL TRIAL SERVICES AGREEMENT This Agreement is effective October 4, 2011 (“Effective Date”) by and between: Harvard Clinical Research Institute, Inc. (“HCRI”)Clinical Trial Services Agreement • October 11th, 2011 • InspireMD, Inc. • Surgical & medical instruments & apparatus • Massachusetts
WHEREAS, InspireMD (“Sponsor”) desires to engage HCRI for the purpose of providing Clinical Trial Services, as defined in Exhibit A to this Agreement, which will serve as the Scope of Work and budget for the Agreement, for the protocol for the “MGuard Stent System Clinical Trial in Patients with Acute Myocardial Infarction” Study, which shall be developed by HCRI under a separate consulting agreement, with such Protocol being incorporated by reference; and
CLINICAL TRIAL SERVICES AGREEMENT*Clinical Trial Services Agreement • May 23rd, 2011 • Radius Health, Inc. • Blank checks • New York
This Clinical Trial Services Agreement (this “Agreement”) is entered into as of March 29, 2011 (“Effective Date”) by and between RADIUS HEALTH, INC., a Delaware corporation (“Radius”) and NORDIC BIOSCIENCE CLINICAL DEVELOPMENT VII A/S, a Danish corporation (“NB”) that is a wholly-owned subsidiary of Nordic Bioscience Clinical Development A/S and sets forth the terms and conditions that will apply to the provision by NB to Radius of certain services.
CLINICAL TRIAL SERVICES AGREEMENT AMENDMENT NO. 5 TO WORK STATEMENT NB-3Clinical Trial Services Agreement • February 25th, 2016 • Radius Health, Inc. • Pharmaceutical preparations
Pursuant to Section 2.3, 2.11 and 11.7 of the Agreement, the parties wish to enter into this Amendment No. 5 to Work Statement NB-3 (“Amendment No. 5”) effective as of January 15, 2016 (“Amendment Date”). Capitalized terms used in this Amendment No. 5 and not defined herein are used with the meanings ascribed to them in the Agreement and Work Statement NB-3.
CLINICAL TRIAL SERVICES AGREEMENT AMENDMENT NO. 8 TO WORK STATEMENT NB-1Clinical Trial Services Agreement • February 25th, 2016 • Radius Health, Inc. • Pharmaceutical preparations
Pursuant to Section 2.3, 2.11 and 11.7 of the Agreement, the parties wish to enter into this Amendment No. 8 to Work Statement NB-1 (“Amendment No. 8”) effective as of August 15, 2014 (“Amendment Date”). Capitalized terms used in this Amendment No. 8 and not defined herein are used with the meanings ascribed to them in the Agreement and Work Statement NB-1.
CLINICAL TRIAL SERVICES AGREEMENT AMENDMENT NO. 2 TO WORK STATEMENT NB-3Clinical Trial Services Agreement • May 6th, 2015 • Radius Health, Inc. • Pharmaceutical preparations
Pursuant to Section 2.3, 2.11 and 11.7 of the Agreement, the parties wish to enter into this Amendment No. 2 to Work Statement NB-3 (“Amendment No. 2”) effective as of March 23, 2015 (“Amendment Date”). Capitalized terms used in this Amendment No. 2 and not defined herein are used with the meanings ascribed to them in the Agreement and Work Statement NB-3.
CLINICAL TRIAL SERVICES AGREEMENT AMENDMENT NO. 4 TO WORK STATEMENT NB-3Clinical Trial Services Agreement • February 25th, 2016 • Radius Health, Inc. • Pharmaceutical preparations
Pursuant to Section 2.3, 2.11 and 11.7 of the Agreement, the parties wish to enter into this Amendment No. 4 to Work Statement NB-3 (“Amendment No. 4”) effective as of October 21, 2015 (“Amendment Date”). Capitalized terms used in this Amendment No. 4 and not defined herein are used with the meanings ascribed to them in the Agreement and Work Statement NB-3.
CLINICAL TRIAL SERVICES AGREEMENT AMENDMENT NO. 3Clinical Trial Services Agreement • August 6th, 2015 • Radius Health, Inc. • Pharmaceutical preparations
The parties wish to enter into this Amendment No. 3 effective as of July 8, 2015 (“Amendment Date”). Capitalized terms used in this Amendment No. 3 and not defined herein are used with the meanings ascribed to them in this Agreement.
CLINICAL TRIAL SERVICES AGREEMENT AMENDMENT NO. 6 TO WORK STATEMENT NB-1Clinical Trial Services Agreement • August 12th, 2014 • Radius Health, Inc. • Blank checks
Pursuant to Section 2.3, 2.11 and 11.7 of the Agreement, the parties wish to enter into this Amendment No. 6 to Work Statement NB-1 (“Amendment No. 6”) effective as of July 22, 2014 (“Amendment Date”). Capitalized terms used in this Amendment No. 6 and not defined herein are used with the meanings ascribed to them in the Agreement and Work Statement NB-1.
ContractClinical Trial Services Agreement • May 5th, 2020 • Massachusetts
EX-10.1 2 q1100194_ex10-1.htm CLINICAL TRIAL SERVICES AGREEMENT This Agreement is effective October 4, 2011 (“Effective Date”) by and between: Harvard Clinical Research Institute, Inc. (“HCRI”) 930 Commonwealth Avenue Boston, Massachusetts 02215 and InspireMDLtd. (“InspireMD”) 3 Menorat Hamor St. Tel Aviv, Israel “MGuard Stent System Clinical Trial in Patients with Acute Myocardial Infarction” 1 WHEREAS, InspireMD (“Sponsor”) desires to engage HCRI for the purpose of providing Clinical Trial Services, as defined in Exhibit A to this Agreement, which will serve as the Scope of Work and budget for the Agreement, for the protocol for the “MGuard Stent System Clinical Trial in Patients with Acute Myocardial Infarction” Study, which shall be developed by HCRI under a separate consulting agreement, with such Protocol being incorporated by reference; and WHEREAS, HCRI and its professionals have experience in the development and administration of clinical trials of various Investigational Prod
Re: Letter of Intent for Clinical Trial Services to be provided by Nordic Bioscience A/S (“NB”) to Radius Health, Inc. (“Radius”)Clinical Trial Services Agreement • December 12th, 2013 • Radius Health, Inc. • Blank checks
Radius and NB are parties to that certain Clinical Trial Services Agreement dated as of the March 29, 2011 (the “CTS Agreement”) and a certain Work Statement NB-3 under the CTS Agreement. Pursuant to Section 2.1 of the CTS Agreement, we have been negotiating the definitive terms of an Amendment No. 1 to Work Statement NB-3 to a Period 2 extension of the clinical study that is the subject of Work Statement NB-3 entitled: BA058-05-005 “An Extension Study to Evaluate 24 Months of Standard-of-Care Osteoporosis Management Following Completion of 18 Months of BA058 or Placebo Treatment in Protocol BA058-05-00” (the “Study”). Amendment No. 1 to Work Statement NB-3 provides for payment by Radius to NB of both cash and equity compensation in consideration of the services provided by NB, with the equity portion of such compensation to be made pursuant to an Amendment No. 2 to the Amended and Restated Stock Issuance Agreement entered into by the parties as of May 16, 2011.
CLINICAL TRIAL SERVICES AGREEMENT AMENDMENT NO. 7 TO WORK STATEMENT NB-1Clinical Trial Services Agreement • August 12th, 2014 • Radius Health, Inc. • Blank checks
Pursuant to Section 2.3, 2.11 and 11.7 of the Agreement, the parties wish to enter into this Amendment No. 7 to Work Statement NB-1 (“Amendment No. 7”) effective as of July 22, 2014 (“Amendment Date”). Capitalized terms used in this Amendment No. 7 and not defined herein are used with the meanings ascribed to them in the Agreement and Work Statement NB-1.
CLINICAL TRIAL SERVICES AGREEMENT AMENDMENT NO. 9 TO WORK STATEMENT NB-1Clinical Trial Services Agreement • May 6th, 2015 • Radius Health, Inc. • Pharmaceutical preparations
Pursuant to Section 2.3, 2.11 and 11.7 of the Agreement, the parties wish to enter into this Amendment No. 9 to Work Statement NB-1 (“Amendment No. 9”) effective as of 12 March, 2015 (“Amendment Date”). Capitalized terms used in this Amendment No. 9 and not defined herein are used with the meanings ascribed to them in the Agreement and Work Statement NB-1.
CLINICAL TRIAL SERVICES AGREEMENT AMENDMENT NO. 3 TO WORK STATEMENT NB-1Clinical Trial Services Agreement • November 14th, 2013 • Radius Health, Inc. • Blank checks
Pursuant to Section 2.3, 2.11 and 11.7 of the Agreement, the parties wish to enter into this Amendment No. 3 to Work Statement NB-1 (“Amendment No. 3”) effective as of November 6, 2013 (“Amendment Date”). Capitalized terms used in this Amendment No. 3 and not defined herein are used with the meanings ascribed to them in the Agreement and Work Statement NB-1.
ContractClinical Trial Services Agreement • September 12th, 2017
SMLOUVA OPROVEDENÍ KLINICKÉHO HODNOCENÍ Nordic Bioscience Clinical Development A/S a Endokrinologický ústav jako ZDRAVOTNICKÉ ZAŘÍZENÍ
ContractClinical Trial Services Agreement • December 5th, 2023
GILEAD SCIENCES, INC. GILEAD SCIENCES, INC. CLINICAL TRIAL SERVICES AGREEMENT SMLOUVA O POSKYTOVÁNÍ SLUŽEB V KLINICKÉM HODNOCENÍ This Clinical Trial Services Agreement (“Agreement”) is made effective as of its publication in Contract Register(“Effective Date”) by and between Gilead Sciences, Inc., a Delaware corporation having a principal place of business at 333 Lakeside Drive, Foster City, California 94404 “Gilead”), and Nemocnice Na Homolce, Registration No: 00023884, having an address at Roentgenova 37/2, 150 30 Praha 5, Czech Republic (“Service Provider”).Account IQVIA RDS Czech Republic s.r.o., Registration No. 24768651, place of business located at Pernerova 691/42, 186 00 Praha 8 – Karlín, Czech Republic (the “CRO”) is serving as Gilead's contract research organization for the Trial. Gilead and Service Provider are sometimes referred to herein individually as a “Party” and collectively as the “Parties.” Tato Smlouva o poskytování služeb v klinickém hodnocení („Smlouva“) je
Confidential Treatment Requested Under 17 C.F.R. §§ 200.80(b)(4) and 240.24b-2 CLINICAL TRIAL SERVICES AGREEMENT AMENDMENT NO. 1 TO WORK STATEMENT NB-1Clinical Trial Services Agreement • December 15th, 2011 • Radius Health, Inc. • Blank checks
Pursuant to Section 2.3, 2.11 and 11.7 of the Agreement, the parties wish to enter into this Amendment No. 1 to Work Statement NB-1 (“Amendment No. 1”) effective as of December 9, 2011 (“Amendment Date”). Capitalized terms used in this Amendment No. 1 and not defined herein are used with the meanings ascribed to them in the Agreement and Work Statement NB-1.
CLINICAL TRIAL SERVICES AGREEMENT AMENDMENT NO. 2 TO WORK STATEMENT NB-1Clinical Trial Services Agreement • June 22nd, 2012 • Radius Health, Inc. • Blank checks
Pursuant to Section 2.3, 2.11 and 11.7 of the Agreement, the parties wish to enter into this Amendment No. 2 to Work Statement NB-1 (“Amendment No. 2”) effective as of June 18, 2012 (“Amendment Date”). Capitalized terms used in this Amendment No. 2 and not defined herein are used with the meanings ascribed to them in the Agreement and Work Statement NB-1.
CLINICAL TRIAL SERVICES AGREEMENT AMENDMENT NO. 1 TO WORK STATEMENT NB-3Clinical Trial Services Agreement • March 10th, 2014 • Radius Health, Inc. • Blank checks
Pursuant to Section 2.3, 2.11 and 11.7 of the Agreement, the parties wish to enter into this Amendment No. 1 to Work Statement NB-3 (“Amendment No. 1”) effective as of February 28, 2014 (“Amendment Date”). Capitalized terms used in this Amendment No. 3 and not defined herein are used with the meanings ascribed to them in the Agreement and Work Statement NB-3.
SERVICES AGREEMENTClinical Trial Services Agreement • October 27th, 2017
